Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. Wrangle JM, et al. Among authors: rhode pr. Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5. Lancet Oncol. 2018. PMID: 29628312 Free PMC article. Clinical Trial.
Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein.
Belmont HJ, Price-Schiavi S, Liu B, Card KF, Lee HI, Han KP, Wen J, Tang S, Zhu X, Merrill J, Chavillaz PA, Wong JL, Rhode PR, Wong HC. Belmont HJ, et al. Among authors: rhode pr. Clin Immunol. 2006 Oct;121(1):29-39. doi: 10.1016/j.clim.2006.05.005. Epub 2006 Jun 30. Clin Immunol. 2006. PMID: 16807113
Targeting activity of a TCR/IL-2 fusion protein against established tumors.
Wen J, Zhu X, Liu B, You L, Kong L, Lee HI, Han KP, Wong JL, Rhode PR, Wong HC. Wen J, et al. Among authors: rhode pr. Cancer Immunol Immunother. 2008 Dec;57(12):1781-94. doi: 10.1007/s00262-008-0504-7. Epub 2008 Mar 28. Cancer Immunol Immunother. 2008. PMID: 18369620 Free PMC article.
Novel human interleukin-15 agonists.
Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, Yovandich JL, Rhode PR, Wong HC. Zhu X, et al. Among authors: rhode pr. J Immunol. 2009 Sep 15;183(6):3598-607. doi: 10.4049/jimmunol.0901244. Epub 2009 Aug 26. J Immunol. 2009. PMID: 19710453 Free PMC article.
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
Jiao JA, Kelly AB, Marzec UM, Nieves E, Acevedo J, Burkhardt M, Edwards A, Zhu XY, Chavaillaz PA, Wong A, Wong JL, Egan JO, Taylor D, Rhode PR, Wong HC. Jiao JA, et al. Among authors: rhode pr. Thromb Haemost. 2010 Jan;103(1):224-33. doi: 10.1160/TH09-06-0400. Epub 2009 Oct 26. Thromb Haemost. 2010. PMID: 20062929 Free PMC article.
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. Fishman MN, et al. Among authors: rhode pr. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12. Clin Cancer Res. 2011. PMID: 21994418 Free PMC article. Clinical Trial.
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR, Wong HC. Xu W, et al. Among authors: rhode pr. Cancer Res. 2013 May 15;73(10):3075-86. doi: 10.1158/0008-5472.CAN-12-2357. Epub 2013 May 3. Cancer Res. 2013. PMID: 23644531 Free PMC article.
35 results